Navigation Links
Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
Date:6/14/2010

For more information about Onyx, visit the company's website at www.onyx-pharm.com.

Forward Looking Statements

This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management.  Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.  These factors include those discussed in Bayer's public reports which are available on the Bayer Web site at www.bayer.com.  The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

This news release contains "forward-looking statements" of Onyx within the meaning of the federal securities laws.  These forward-looking statements include without limitation, statements regarding the progress and results of the clinical development, safety, regulatory processes, commercialization efforts or commercial potential of Nexavar.  These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including risks related to the development and commercialization of pharmaceutical products.  Any statements contained in this press release that are not statements of historical fact may b
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; Onyx Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Poniard Announces Final Data from Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer
2. Onyx Pharmaceuticals Presents Interim Results of Phase 1b Carfilzomib Combination Trial
3. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
4. NeuroDerm Successfully Completes Enrollment and Dosing in a Phase 1 Clinical Study of ND0611 Dermal Patch for Parkinsons Disease
5. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
6. Bayer HealthCare Pharmaceuticals, Inc. Announces Results of a Phase 3 Clinical Trial of Gadobutrol
7. Mpex Pharmaceuticals Presents Positive Phase 2 Clinical Trial Results of Aeroquin(TM) (MP-376) Treatment in Cystic Fibrosis Patients
8. CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate
9. QRxPharma Successfully Completes Comparative Phase 1 Proof-of-Concept Study for MoxDuo(R) CR Tablet Formulation
10. QRxPharma Releases Additional Pivotal Phase 3 Combination Rule Study Data for MoxDuo(R)IR in Patients with Post-Surgical Pain
11. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Calif. , May 20, 2013   Life ... announced that its Applied Biosystems™ 3500 Dx and 3500xL ... Commission for Protection against Health Risks in ... a major extension of Life Technologies, capabilities to serve ... with Sanger -based solutions.  ...
(Date:5/20/2013)... BETHESDA, Md. , May 20, 2013  TNI ... diseases through the activation and mobilization of the body,s ... trading on the OTC Markets, OTCQB marketplace under the ... able to view the real-time Level II stock quotes ... Noreen Griffin , CEO of TNI BioTech, ...
(Date:5/20/2013)... 2013 Decision Resources, one of the ... and healthcare issues, finds that surveyed U.S. and ... effect on quality of life is among the ... level of subjectivity and variability of tests used ... state that it is difficult to differentiate therapies ...
Breaking Medicine Technology:Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 2Life Technologies Announces Regulatory Approval of 3500 Dx Series Genetic Analyzers in Mexico 3TNI BioTech, Inc. Stock to Begin Trading on the OTCQB Marketplace 2TNI BioTech, Inc. Stock to Begin Trading on the OTCQB Marketplace 3For Chronic Obstructive Pulmonary Disease, Surveyed Pulmonologists Indicate That Improved Effect on Quality of Life is One of the Greatest Unmet Needs 2
... , CINCINNATI, Sept. 11 Kendle (Nasdaq: ... research organization, today announced that its regulatory affairs experts ... the Regulatory Affairs Professionals Society (RAPS) Annual Conference and ... Convention Center in Philadelphia. Demonstrating its leadership position in ...
... , , ... schedule of events at the Cardiovascular Research Foundation,s (CRF) annual ... 21st to Friday, September 25th, in San Francisco, CA. at ... world,s largest events for those performing cardiac diagnostics and interventions. ...
Cached Medicine Technology:Kendle Experts to Share Insights at the Regulatory Affairs Professionals Society Annual Conference and Exhibition 2Kendle Experts to Share Insights at the Regulatory Affairs Professionals Society Annual Conference and Exhibition 3InfraReDx to Showcase the LipiScan(TM) Coronary Imaging System at the Cardiovascular Research Foundation's (CRF) Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Meeting 2
(Date:5/20/2013)... May 20, 2013 This summer, digital ... world will make the pilgrimage to San Diego, CA, ... Digital Health Summer Summit produced by Living ... unique forum to showcase the latest digital health innovations, ... and network with some of industry’s most brilliant thinkers ...
(Date:5/20/2013)... 2013 Adeptia Inc., a ... business process integration solutions, today announced the ... integration solution. Version 6.0 is the ... automates business processes involving data access, validation, ... user interaction for real-time decision-making and exception-handling. ...
(Date:5/20/2013)... MONDAY, May 20 (HealthDay News) -- Although many ... physician on staff to help improve outcomes, new ... to patients. Since one-third of teaching hospitals ... in Europe staff a nighttime physician in the ... while siphoning doctors away from hospitals with fewer ...
(Date:5/20/2013)... In celebration of National Women’s Health ... achieved at The Feinstein Institute for Medical Research ... Advancing Women in Science and Medicine (AWSM) , hosted ... Scientists, educators, business and community leaders from the region ... women in science. , “Women face unique barriers ...
(Date:5/20/2013)... it about toothpaste that transforms the sweet flavor of ... to that mysterious sensory phenomenon in colorful, animated ... Chemical Society,s award-winning Bytesize Science video series ... world,s largest scientific society, explains that the mainstay ingredients ... or SLS for short. When you brush your teeth, ...
Breaking Medicine News(10 mins):Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 2Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 3Health News:Living in Digital Times Brings Together Leaders in Digital Health for Summer Summit in San Diego 4Health News:Adeptia Announces New Release of Enterprise Business Integration Solution 2Health News:Adeptia Announces New Release of Enterprise Business Integration Solution 3Health News:Nighttime Docs at ICUs Don't Boost Patient Outcomes: Study 2Health News:North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week 2Health News:North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week 3
... Childhood obesity can lead to type 2 diabetes, asthma, ... youth are likely to be obese as adults, experience ... incur higher healthcare costs. In an article published in ... of Preventive Medicine, researchers report that children living ...
... Oct. 27 HealthSouth,Corporation (NYSE: HLS ) today, ... is reaffirming its previously announced full year 2008,guidance and ... believes remain sound., In addition, HealthSouth noted the ... million in debt year to date,through October 27, 2008, ...
... Oct. 27 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ) ... annual,BIO Investor Forum on Thursday, October 30, 2008 at ... in San Francisco, California., Steve Worland, Ph.D., President ... of Anadys and an update on its development,programs., ...
... Mich. To tackle the growing number of psychiatric cases in ... of Michigan State University doctors from the colleges of Osteopathic ... across the state via video conference. , On a ... up to 10 patients each from as far away as ...
... ANN ARBOR, Mich., Oct. 27 Parrish Medical ... implemented Clinical,Xpert CareFocus(TM) and Clinical Xpert Navigator which ... workflow solutions from the Healthcare business of,Thomson Reuters., ... patients,within a hospital and give clinicians access to ...
... even in combo, an effective long-term treatment , , MONDAY, ... methotrexate are safe and effective for long-term, continuous treatment ... In a three-year study that enrolled about 600 patients, ... methotrexate alone, others took etanercept alone, and another group ...
Cached Medicine News:Health News:Green neighborhoods may reduce childhood obesity 2Health News:HealthSouth Reaffirms Business Fundamentals and Full Year 2008 Guidance 2Health News:HealthSouth Reaffirms Business Fundamentals and Full Year 2008 Guidance 3Health News:Anadys Pharmaceuticals to Present at Bio Investor Forum 2Health News:MSU doctors bring much-needed psychiatric care to rural areas via technology 2Health News:Parrish Medical Center Deploys Clinical Xpert(TM) Solutions from Thomson Reuters 2Health News:Parrish Medical Center Deploys Clinical Xpert(TM) Solutions from Thomson Reuters 3Health News:Etanercept, Methotrexate Safe for Juvenile RA 2
Troutman tying forceps are curved, delicate, bullet shape, with tying platforms. Flat pattern. Ultra fine platforms ideal for 10-0 or 11-0 suture material. Platforms fully meet to hold suture firmly....
Fine tying forceps, standard with smooth jaws. For 7-0 to 9-0 sutures....
Tennant stainless steel tying forceps is extra delicate, straight with smooth jaws, 6 mm long platform, round handle with guide pin. For 9-0 to 11-0 sutures....
Curved shafts and tips with tying surfaces. Wide serrated handle with dull finish. Overall length 4.3 inches....
Medicine Products: